Welcome to our dedicated page for Silo Pharma SEC filings (Ticker: SILO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Silo Pharma, Inc. (Nasdaq: SILO) SEC filings page on Stock Titan provides direct access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into Silo’s status as a developmental-stage biopharmaceutical and cryptocurrency treasury company, its capital structure, and its governance and compliance framework.
For investors analyzing Silo’s biopharmaceutical programs and digital assets strategy, key filings include current reports on Form 8-K, the Definitive Proxy Statement (DEF 14A), and registration statements such as Form S-1. Recent 8-Ks describe material events including the launch of a cryptocurrency advisory board, asset purchases related to crypto software and domains, Nasdaq minimum bid price notifications, strategic agreements with Fireblocks for digital asset custody, and securities purchase agreements for registered direct offerings and concurrent private placements.
The Form S-1 registration statement filed in October 2025 details the resale of shares issuable upon exercise of investor and placement agent warrants issued in a financing transaction, including warrant terms, exercise prices, and potential proceeds if exercised. This document helps readers understand how warrant exercises could affect Silo’s share count and capital resources.
Silo’s DEF 14A proxy statement outlines matters submitted to shareholders at the 2025 annual meeting, such as director elections, ratification of the independent registered public accounting firm, authorization of a reverse stock split within a specified range, and an amendment to increase shares reserved under the equity incentive plan. An 8-K reporting the voting results shows how shareholders acted on these proposals.
Additional 8-K filings cover topics such as an evaluation license and option agreement with the University of Maryland, Baltimore for intellectual property related to central nervous system-homing peptides and the establishment of a cryptocurrency advisory board with related equity compensation. Together, these documents provide a regulatory record of Silo’s efforts to advance its SPC-15 and SP-26 programs, manage listing compliance on the Nasdaq Capital Market, and implement its crypto treasury strategy.
On Stock Titan, these filings are updated as they appear on EDGAR, and AI-powered tools can be used to quickly surface items related to financings, listing compliance, governance changes, and strategic agreements within Silo Pharma’s disclosure history.
Silo Pharma, Inc. entered into an asset purchase agreement to acquire the software for the QwikAgents web-based application and related domain names from Many Ads Inc. In exchange for these assets, Silo issued 2,100,000 shares of its common stock to the seller.
The agreement includes customary representations, warranties and covenants, and the seller agreed to indemnify Silo for issues such as misrepresentations, software infringement, and specified misconduct. The shares were issued in a private, unregistered transaction relying on a securities law exemption.
Silo Pharma, Inc. filed its annual report describing a developmental-stage biopharmaceutical and cryptocurrency company focused on CNS and pain disorders. The pipeline includes SPC-15, an intranasal PTSD and anxiety treatment advancing toward an IND, SP-26 ketamine implants for fibromyalgia, SPC-14 for Alzheimer’s disease and SPU-16 for multiple sclerosis.
Silo licenses key IP from Columbia University, the University of Maryland, Baltimore and Medspray for nasal delivery technology, and reports five issued patents with 20 pending applications. In 2025 it added a cryptocurrency treasury strategy, holding crypto assets of $221,817 and staking $98,584 to earn yield.
The company highlights significant regulatory and clinical risks around psychedelic-based therapies, controlled substance compliance and financing needs. As of March 27, 2026, it had 14,166,593 common shares outstanding, three full-time employees and a Board-authorized stock repurchase program of up to $1 million through December 31, 2026.
Silo Pharma, Inc. reported two equity-related actions. The company issued 848,320 shares of common stock to its investor relations consultant as a $250,000 commitment fee, valued at $0.2947 per share, in connection with restarting a service agreement. The issuance is an unregistered transaction under Section 4(a)(2) of the Securities Act and provides no cash proceeds to the company.
The board of directors also approved a stock repurchase program authorizing the company to buy back up to $1 million of its common stock through open market or privately negotiated transactions. Silo Pharma had 13,318,273 shares outstanding as of November 13, 2025, providing context for the potential scale of repurchases.
Anson Funds-linked entities report a 4.9% stake in Silo Pharma, Inc. They collectively beneficially own 699,486 shares of Silo Pharma common stock, including shares underlying warrants, as of the reporting described for 12/31/2025.
Anson Funds Management LP and Anson Advisors Inc. act as co‑investment advisers to private funds that hold the shares, with related general partner and individual principals sharing voting and disposition power. The warrants include a 4.99% beneficial ownership limitation, which caps how much of the company can be owned through warrant exercise at any time. The securities are described as acquired and held in the ordinary course of business, without the purpose or effect of changing or influencing control of Silo Pharma.
Silo Pharma, Inc. received an updated large-shareholder report showing that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC together beneficially own 1,478,164 shares of common stock, or 9.99% of the company, as of December 31, 2025.
This position is entirely tied to warrants held by Intracoastal, including 833,334 shares from one warrant and 644,830 shares from a second warrant. Additional warrants for up to 1,866,741 more shares are subject to 9.99% and 4.99% blocker provisions that limit how many shares can be exercised at any time. Without these blockers, the reporting group would beneficially own 3,344,905 shares.
SEG Opportunity Fund, LLC has filed an amended Schedule 13G for Silo Pharma, Inc. reporting that it no longer beneficially owns any shares of the company’s common stock. The filing shows 0 shares with 0.0% of the class, with no sole or shared voting or dispositive power.
The report confirms that the securities previously held were not acquired or held for the purpose of changing or influencing control of Silo Pharma, and that SEG Opportunity Fund’s ownership has fallen to 5% or less of the outstanding common stock.
Silo Pharma, Inc. Chief Executive Officer and director Eric Weisblum reported purchases of the company’s common stock. On December 15, 2025, he bought 2,500 shares at $0.41 per share and another 2,500 shares at $0.42 per share. After these transactions, he directly beneficially owned 216,932 shares of Silo Pharma common stock.
Silo Pharma, Inc. (SILO) CEO and director Eric Weisblum reported open-market purchases of company stock. On 11/20/2025, he bought 1,000 shares of common stock at $0.37 per share. On 11/21/2025, he purchased another 1,000 shares at $0.365 per share. Following these transactions, Weisblum beneficially owns 211,932 shares of Silo Pharma common stock, held directly.
Silo Pharma, Inc. insider share purchases reported
A reporting person serving as both a director and Chief Executive Officer of Silo Pharma, Inc. (SILO) filed a Form 4 disclosing open‑market purchases of the company’s common stock. On November 18, 2025, the insider purchased 7,500 shares at a weighted average price of $0.4033 per share. On November 19, 2025, the insider purchased an additional 4,500 shares at a weighted average price of $0.405 per share. Following these transactions, the insider directly owns 209,932 shares of Silo Pharma common stock.
Silo Pharma, Inc. (SILO) filed its Q3 2025 10‑Q, reporting a net loss of $1,110,438 for the quarter and $3,346,168 for the nine months ended September 30, 2025. License fee revenue was $18,025 in the quarter and $54,076 year‑to‑date, with cost of revenues of $20,687 in the quarter.
Operating expenses were led by R&D at $543,615 in the quarter ($1,854,824 YTD), plus compensation and professional fees. As of September 30, 2025, cash and cash equivalents were $3,917,627, short‑term investments $1,948,579, total assets $6,384,681, and working capital $5,456,030. The company states it has sufficient cash and liquid short‑term investments to meet obligations for a minimum of twelve months from the date of the filing.
During 2025, Silo completed a May public offering with net proceeds of $1,593,897 and received warrant exercise proceeds of $500,000 on June 6 and $634,922 during August–September. It also issued 750,000 shares valued at $518,225 for software assets, recorded as R&D. Crypto assets totaled $72,283 at fair value as of September 30, 2025. Shares outstanding were 13,318,273 as of November 13, 2025.